Editorial: States and state transitions are all that really matter

Journal of Urology

Volumn 168, Issue 6, 2002, Pages 2451-2453

  Scher, Howard I ^a   Kelly, William K ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CETUXIMAB; ESTRAMUSTINE; ETOPOSIDE; IRINOTECAN; MITOXANTRONE; NAVELBINE; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; TAXANE DERIVATIVE; VINBLASTINE;

BONE METASTASIS; BONE SCINTISCANNING; CANCER COMBINATION CHEMOTHERAPY; CANCER PAIN; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; EDITORIAL; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

EID: 0036895343     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)64165-1     Document Type: Editorial

References (22)

1. Kelly, W. K., Curley, T., Slovin, S., Heller, G., McCaffrey, J., Bajorin, D. et al: Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol, 19: 44, 2001
2. Scher, H. I. and Heller, G.: Clinical states in prostatd cancer: Towards a dynamic model of disease progression. Urology, 55: 323, 2000
3. Tannock, I. F., Osoba, D., Stockler, M. R., Ernst, S., Neville, A. J., Moore, M. J. et al: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol, 14: 1756, 1996
4. Kantoff, P. W., Halabi, S., Conaway, M., Picus, J., Kirscher, V., Trump, D. et al: Hydrocortisone with or without mitoxantrone in men with horlone-refractory prostate cancer: Results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol, 18: 2506, 1999
5. Moore, M. J., Tannock, I. F., Osoba, D., Armitage, G., Neville, P. and Murphy, K.: Mitoxantrone (M) + prednisone (P) in patients (PTS) with hormonally resistant prostate cancer. Use of a quality of life endpoint. Proc Am Soc Clin Oncol, 11: 215, 1992
6. Newling, D. W. W.: Orchiectomy versus zoladex and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Cancer, 72: 3793, 1993
7. Saltz, L., Meropol, N. J., Loehrer, P. J., Waksal, J., Needle, M. N. and Mayer, R. J.: Single agent IMC-C224 (ErbituxTM) has activity in CPT-11-refractory colorectal cancer (CRC) that expressed the epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol, 21: 127a, 2002
8. Bubley, G. J., Carducci, M., Dahut, W., Dawson, N., Daliani, D., Eisenberger, M. et al: Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the PSA Working Group. J Clin Oncol, 17: 3461, 1999
9. Fleming, T. R. and DeMets, D. L.: Surrogate end points in clinical trials: Are we being misled. Ann Intern Med, 125: 605, 1996
10. Verbel, D. A., Heller, G., Kelly, W. K. and Scher, H. I.: Quantifying the amount of variation in survival explained by PSA. Clin Ca Res, 8: 2576, 2002
11. Eisenberger, M. A., Simon, R., O'Dwyer, P. J., Wittes, R. E. and Friedman, M. A.: A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol, 3: 827, 1985
12. Petrylak, D. P., MacArthur, R. B., O'Connor, J., Shelton, G., Judge, T., Balog, J. et al: Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol, 17: 958, 1998
13. Savarese, D. M., Halabi, S., Hars, V., Akerley, W. L., Taplin, M. E., Godley, P. A. et al: Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780 (Cancer and Leukemia Group B). J Clin Oncol, 19: 2509, 2001
14. Tu, S. M., Millikan, R. E., Mengistu, B., Delpassand, E. S., Amato, R. J., Pagliaro, L. C. et al: Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: A randomised phase II trial. Lancet, 357: 326, 2001
15. Smaletz, O., Scher, H. I., Kelly, W. K., Verbel, D. A., Regan, K., Curley, T. et al: A nomogram for overall survival of patients with castrate-metastatic prostate cancer (PC). Proc Am Soc Clin Oncol, 20: 183a, 2001
16. Seidman, A. D., Scher, H. I., Petrylak, D., Dershaw, D. and Curley, T.: Estramustine and vinblastine: Use of prostate specific antigen as a clinical trial end point in hormone refractory prostatic cancer. J Urol, 147: 931, 1992
17. Hudes, G. R., Greenberg, R., Krigel, R. L., Fox, S., Scher, R., Litwin, S. et al: Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol, 10: 1754, 1992
18. Pienta, K. J., Redman, B. G., Bandekar, R., Strawderman, M., Cease, K., Esper, P. S. et al: A phase II trial of oral estramustine and oral etoposide in hormone refractory prostate cancer. Urology, 50: 401, 1997
19. Reese, D., Burris, H., Belledgrun, A., White, L., O'Rourke, T., Yates, B. et al: @ phase I/II study of Navelbine (vinorelbine) and estramustine in the treatment of hormone refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol, 15: 673, 1996
20. Hudes, G., Ross, E., Roth, B., Balshem, A., Loehrer, P. J., Ramsey, H. et al: Improved survival for patients with hormone-refractory prostate cancer receiving estramustine-based antimicrotubule therapy: Final report of a Hoosier Oncology Group and Fox Chase Network phase III trial comparing vinblastine and vinblastine plus oral estramustine. Proc Am Soc Clin Oncol, 21: 177a, 2002
21. Oh, W., Halabi, S., Kelly, W. K., Godley, P. A., Werner, C., Kantoff, P. W. et al: A phase II study of estramustine, docetaxel, and carboplatin (EDC) with G-CSF support in men with hormone-refractory prostate cancer (HRPC): CALGB 99813. Proc Am Soc Clin Oncol, 21: 195a, 2002
22. Hussain, M., Petrylak, D., Fisher, E., Tangen, C. and Crawford, D.: Docetaxel (taxotere) and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: Scientific basis and ddsign of Southwest Oncology Group Study 9916. Semin Oncol, 26: 55, 1999